Navigation Links
Delcath Highlights Phase III Trial Results Presented at ASCO
Date:6/5/2010

that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the acceptability of the Phase III clinical trial data by the FDA, our ability to successfully complete an FDA new drug application, acceptance of the new drug application by the FDA, approval by the FDA or other regulatory authorities of the current or future drug delivery system for the treatment of metastatic melanoma, our ability to successfully complete other clinical trials and secure regulatory approval of our current or future drug-delivery system for the treatment of other liver cancers and other organs, the potential of chemosaturation therapy via PHP as a treatment for patients with terminal metastatic disease in the liver, actions by the FDA or other regulatory agencies  and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.


'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Delcath Adds University of Pittsburgh Medical Center to Phase III Trial
2. Jonathan Lewis, M.D., Ph.D. Steps Down From Delcath Systems Board of Directors
3. Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors
4. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
5. Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma
6. Delcath Systems Granted Third Orphan Drug Designation
7. Delcath Enters Agreement to Sell 869,565 Units
8. Delcath Systems Receives Preliminary Notification of Inclusion in Russell 3000(R) Index
9. Eamonn Hobbs Appointed President & CEO of Delcath Systems, Inc.
10. Delcath Systems Names Michael D. Dellario as Vice President, Global Marketing
11. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire-iReach/ -- DeepResearchReports.com ... China Acetic Acid Industry" and "2014 Deep Research ... reports to its research database. Photo ... Deep Research Report on Global and China Acetic ... report on China and ...
(Date:9/18/2014)... 18, 2014  Health Enhancement Products, Inc. (OTCQB: HEPI), a ... bioactive compounds and metabolic processes, is pleased to announce the ... directors. Ms. Nola E. Masterson , a ... board effective September 17, 2014. "We,re very ... our board," states Andrew Dahl , President and CEO. ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Texas ... John Sharp, Texas A&M Health Science Center CEO ... Department of Health and Human Services (HHS), State ... a national pandemic influenza vaccine manufacturing facility in ... an anchor for the Texas A&M Biocorridor – ...
(Date:9/18/2014)... Research and Markets has announced ... Cell Industry Report, 2014-2017" report to their offering. ... that can differentiate into specialized cells and can divide ... therapy can be applied to treatment of cardiovascular diseases, ... diseases, damage or lesion of liver, kidney and other ...
Breaking Biology Technology:Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3
... Therapeutics, Inc., a,privately held biopharmaceutical company, announced today ... will present a corporate,overview at the JMP Securities ... 7 at 9 a.m. ET at the Le ... Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company,focused ...
... 1 Halozyme Therapeutics, Inc.,(Nasdaq: HALO ), ... extracellular matrix, today announced that it will,host a ... 12:15 p.m. EDT. A,webcast of the presentations will ... PRESENTATIONS, -- Strategic Company Overview, Jonathan Lim, ...
... - OncoGenex,Pharmaceuticals, Inc (NASDAQ: OGXI ) will ... on October 2 at 4:30 pm ET in ... City. OncoGenex, President and,Chief Executive Officer, Scott Cormack, ... a discussion of the Company,s lead cancer drug,candidate ...
Cached Biology Technology:Halozyme Therapeutics to Host Research Day for Investors and Analysts 2
(Date:9/18/2014)... the ultimate form of camouflage: you don,t just blend ... is not as uncommon as you might think. Kathryn ... explains that the larval life stages of many marine ... the anatomy that most creatures cannot make transparent. Feller ... shield each individual eye unit with an opaque pigment ...
(Date:9/18/2014)... Clownfish spend their entire lives nestling in the protective ... as babies they sometimes travel hundreds of kilometres across ... by reef fish has been predicted, this is the ... between distant populations has been observed. , Dr Steve ... at the University of Exeter, and colleagues from the ...
(Date:9/17/2014)... were instrumental in the creation of the Santa Ana ... the fire threat potential of the powerful, hot, dry ... an inferno. The index was introduced Sept. 17 by ... San Diego Gas and Electric. , The index includes ... will be used to help fire agencies and other ...
Breaking Biology News(10 mins):Transparent larvae hide opaque eyes behind reflections 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2
... (UW) researchers have gathered evidence that dangerous plaques in ... are fat-laden rough spots in the otherwise smooth walls ... of it, a process known as plaque hemorrhage. The ... flow of oxygen-rich blood is restricted, a heart attack, ...
... A Brazilian scorpion has provided researchers at North ... venom,s effects on the ability of certain cells to ... understanding diseases like pancreatitis or in targeted drug delivery. ... an inflammation of the pancreas. ECU microbiologist Dr. Paul ...
... Science Foundation has bestowed a Faculty Early Career Development ... molecular biologist and geneticist whose work since she joined ... her passion for research and her commitment to training ... Award is an exceptional recognition of exceptional qualities in ...
Cached Biology News:Dangerous plaques in blood vessels rupture by overproducing protein-busting enzymes 2Dangerous plaques in blood vessels rupture by overproducing protein-busting enzymes 3Dangerous plaques in blood vessels rupture by overproducing protein-busting enzymes 4Scorpion venom provides clues to cause, treatment of pancreatitis 2FSU biologist wins $1M Early Career Award from National Science Foundation 2FSU biologist wins $1M Early Career Award from National Science Foundation 3
Human peripheral blood eosinophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Human peripheral blood PBMCs, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood PBMC and T Cells...
Cord blood endothelial progenitor cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Progenitor Cells...
Human plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Biology Products: